TABLE 2.
Summary of Community‐Based Fibrosis Detection Studies
| Study | Target Group | Population Fibrosis Detection Method | Numbers Assessed/Compliance | Outcomes |
|---|---|---|---|---|
| Scarred Liver Project6 (Nottingham, England) | Population | Risk factors | 25,018 screened | 14% kPa 8‐15 |
| FibroScan | 3688 at risk | 6% kPa >15 | ||
| 1239 FibroScans | 39 new cirrhosis diagnoses | |||
| GP compliance unknown | Cost‐effective | |||
| Camden & Islington7 (London, England) | NAFLD | FIB‐4 | 1452 screened | 81% ↓ in referrals |
| ELF | 275 referred | 29% advanced fibrosis | ||
| GP compliance 55% | 14.5% cirrhosis | |||
| Intelligent Liver Function8 (Dundee, Scotland) | Population | Abnormal LBT | 229 intervention group | 45% ↑ in diagnosis |
| FIB‐4 | 64 with abnormal LBTs | Cost‐effective | ||
| FibroScan | GP compliance 50% | Suggests a diagnosis | ||
| Gwent AST Project9 (Gwent, Wales) | Population | Abnormal ALT | 17,770 abnormal ALT | 28% kPa 8‐15 |
| Reflex AST:ALT ratio | 2117 AST:ALT > 1 (12%) | 29% kPa >15 | ||
| FibroScan | 348 FibroScans | 192 advanced fibrosis | ||
| GP compliance 40% | 81% ↑ in cirrhosis diagnosis |